Biogen and Stoke Kick Off Global Phase 3 EMPEROR Study for Dravet Syndrome Treatment
A potential first for a devastating disease, Biogen and Stoke Therapeutics have begun dosing patients in the global Phase 3 EMPEROR trial of zorevunersen.
If successful, this investigational therapy could become the first disease-modifying treatment for Dravet syndrome.
What’s at Stake
Dravet syndrome is:
- A rare, genetic form of epilepsy
- Marked by treatment-resistant seizures and neurodevelopmental impairments
- Caused by mutations in the SCN1A gene
- With no current treatment addressing the root cause
The EMPEROR Study: Quick Facts
- Study goal: Test zorevunersen vs. placebo (“sham”) for safety and effectiveness
- Duration: 52 weeks of treatment after an 8-week baseline period
- Participants: 2–18 years old with confirmed SCN1A mutation (no gain-of-function)
- Locations: U.S., U.K., Japan, with European sites planned
How Zorevunersen Works
Zorevunersen is an antisense oligonucleotide (ASO) — a synthetic RNA molecule designed to restore protein expression and address the underlying genetic defect.
This isn’t just symptom control. It’s aiming at the root cause.
Study Design
Randomization: 1:1 ratio — zorevunersen or sham
Dosing plan:
- Two 70 mg loading doses (Day 1, Week 8)
- Two 45 mg maintenance doses (Week 24, Week 40)
All participants will keep taking their standard-of-care seizure medications.
Primary and Secondary Goals
Primary endpoint:
- Change in major motor seizure frequency at Week 28
Key secondary endpoints:
- Change in seizure frequency at Week 52
- Improvements in behavior and cognition using Vineland-3 measures:
- Expressive & receptive communication
- Interpersonal relationships
- Coping and personal skills
Why Experts Are Watching
“The potential to address the underlying genetic cause and also improve neurodevelopmental symptoms signals a fundamentally new way of treating the disease.”
- Dr. Joseph Sullivan, UCSF
Phase 1/2 and extension studies have already shown:
- Durable seizure reduction
- Ongoing cognitive and behavioral improvements
That’s why there’s high enrollment interest for EMPEROR.
What’s Next
- The trial is already underway in the U.S., U.K., and Japan.
- European sites will follow.
- Eligible participants can roll over into an open-label extension to keep receiving zorevunersen after the study.
Bottom line:
If EMPEROR succeeds, Dravet syndrome patients and their families may finally have a therapy that goes beyond seizure control, tackling the root cause and improving quality of life.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
